Insys Therapeutics (INSY) Tops Q1 EPS by 1c, Miss on Revenues

Insys Therapeutics (NASDAQ: INSY) reported Q1 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $35.96 million versus the consensus estimate of $37.78 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c